The central nervous system (CNS) disorders are the most prevailing and destructive, yet one of the most poorly treated diseases. The central nervous system diseases can arise due to complicated disorders such as ischemic, hemorrhagic, neurodegenerative, inflammatory, and developmental disorders.
&nbsp;
<a style="color: #1155cc;" href="https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market" target="_blank" rel="noopener noreferrer">Gene and Cell Therapies Targeting CNS Disorders Market</a>
&nbsp;
<ul>
<li class="ql-align-justify">The total market size of Gene and Cell Therapies Targeting CNS Disorders was found to be USD 988.8 million in 2020.</li>
<li class="ql-align-justify">Gene and Cell Therapies Targeting CNS Disorders in the US accounted for 86% of the overall market size.</li>
</ul>
&nbsp;
Gene and Cell Therapies Targeting CNS Disorders Market Drivers
&nbsp;
<ul>
<li class="ql-align-justify">Availability of various viral and non-viral vectors</li>
<li class="ql-align-justify">Gene editing tools</li>
<li class="ql-align-justify">Development of animal models</li>
<li class="ql-align-justify">Technological advancements</li>
</ul>
&nbsp;
Gene and Cell Therapies Targeting CNS Disorders Market Barriers
&nbsp;
<ul>
<li class="ql-align-justify">High cost of therapy</li>
<li class="ql-align-justify">Barriers to drug delivery system</li>
<li class="ql-align-justify">Challenges to regulatory approval</li>
</ul>
&nbsp;
Emerging Drugs for Amyotrophic Lateral Sclerosis along with their Key Players
&nbsp;
<ul>
<li class="ql-align-justify">NurOwn: BrainStorm Cell Therapeutics</li>
<li class="ql-align-justify">Engensis: Helixmith</li>
<li class="ql-align-justify">HYNR-CS inj: Corestem</li>
<li class="ql-align-justify">Q Cells: Q therapeutics</li>
<li class="ql-align-justify">VM202: Helixmith</li>
<li class="ql-align-justify">RAPA-501 Autologous T cells: Rapa Therapeutics</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight" target="_blank" rel="noopener noreferrer">Emerging Drug for Multiple Sclerosis</a> along with their Key Player
&nbsp;
<ul>
<li class="ql-align-justify">NurOwn: BrainStorm Cell Therapeutics</li>
</ul>
&nbsp;
Emerging Drugs for Spinal Cord Injury along with their Key Players
&nbsp;
<ul>
<li class="ql-align-justify">Neuro-Cells: Neuroplast</li>
<li class="ql-align-justify">Umbilical Cord Blood Mononuclear Cell: StemCyte</li>
<li class="ql-align-justify">Human spinal cord stem cells: Neuralstem</li>
<li class="ql-align-justify">FAB117-HC: Ferrer Internacional</li>
</ul>
&nbsp;
Emerging Drugs for Alzheimer&rsquo;s Disease along with their Key Players&nbsp;
&nbsp;
<ul>
<li class="ql-align-justify">itMSCs: Stemedica Cell Technologies</li>
<li class="ql-align-justify">AAV-hTERT: Libella Gene Therapeutics</li>
<li class="ql-align-justify">ST-501: Sangamo Therapeutics</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights" target="_blank" rel="noopener noreferrer">Emerging Drugs for Parkinson Disease</a> along with their Key Players
&nbsp;
<ul>
<li class="ql-align-justify">VY-AADC: Hoffmann-La Roche</li>
<li class="ql-align-justify">Lomecel-B: Longeveron</li>
<li class="ql-align-justify">OXB-102: Sio Gene Therapies</li>
<li class="ql-align-justify">PR001: Prevail Therapeutics (Eli Lilly and Company)</li>
<li class="ql-align-justify">Neural Stem Cell-Derived Neurons: NeuroGeneration</li>
<li class="ql-align-justify">AAV2-GDNF: Brain Neurotherapy Bio (AskBio)</li>
</ul>
&nbsp;
Emerging Drug for Huntington's Disease along with their Key Player
&nbsp;
<ul>
<li class="ql-align-justify">Intra-striatal rAAV5-miHTT: UniQure Biopharma&nbsp;</li>
</ul>

Gene and Cell Therapies Targeting CNS Disorders Market 

Gene and Cell Therapies Targeting CNS Disorders Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape 